DUBLIN--(BUSINESS WIRE)--The "Leiomyosarcoma - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
The report offers comprehensive insights into the pipeline landscape for Leiomyosarcoma, a type of cancer. It covers information about more than 10 companies and over 10 pipeline drugs related to Leiomyosarcoma.
The report provides detailed profiles of pipeline drugs, including their clinical and nonclinical stages of development. It also assesses these therapeutics based on various factors such as product type, development stage, route of administration, and molecule type. Additionally, the report highlights any inactive pipeline products in this field.
Furthermore, the report offers a comprehensive overview of the current status and growth prospects within the Leiomyosarcoma pipeline landscape. It includes disease background information and treatment guidelines for Leiomyosarcoma.
The assessment section of the report delves into both commercial and clinical aspects of the pipeline products in development. It provides detailed descriptions of these drugs, including their mechanisms of action, clinical studies, NDA (New Drug Application) approvals (if any), and information about their development activities, including technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related details.
Overall, this report offers a comprehensive and detailed analysis of the Leiomyosarcoma pipeline landscape, providing valuable insights into the current status and future prospects of potential treatments for this condition.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Leiomyosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Leiomyosarcoma.
Leiomyosarcoma Emerging Drugs Chapters
This segment of the Leiomyosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Leiomyosarcoma Emerging Drugs
ADI PEG20: Polaris Group
ADI-PEG 20 is a first-in-class therapeutic approach to deplete arginine and starve cancer cells. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, some cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient's normal cells unharmed. Currently, it is in Phase III stage of clinical trial evaluation to treat Leiomyosarcoma.
AL-3818: Advenchen Laboratories
AL3818 is a novel small molecule PTK inhibitor being developed by Advenchen Laboratories. Advenchen Laboratories is conducting a Phase III study to evaluate the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS).
Leiomyosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Leiomyosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Leiomyosarcoma
There are approx. 10+ key companies which are developing the therapies for Leiomyosarcoma. The companies which have their Leiomyosarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories.
Key Questions Answered
- How many companies are developing Leiomyosarcoma drugs?
- How many Leiomyosarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Leiomyosarcoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Leiomyosarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Leiomyosarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Merck
- Advenchen Laboratories
- Trillium Therapeutics
- PTC Therapeutics
- PharmaMar
- Philogen
- EMD Serono
- Incyte Corporation
- Clovis Oncology, Inc.
Key Products
- Avelumab
- AL3818
- Pembrolizumab
- TTI-621
- PTC596
- ET-743
- L19-hTNF
- M6620
- Itacitinib
- Rucaparib
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Leiomyosarcoma Report Insights
- Leiomyosarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Leiomyosarcoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/s59idt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
